| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
146,000,000 |
| Market
Cap: |
16.22(B) |
| Last
Volume: |
1,035,875 |
Avg
Vol: |
1,333,523 |
| 52
Week Range: |
$92.79 - $212.65 |
|
| Level
I Sector: |
Information Technology |
| Level
II Sector: |
Electronics |
| Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 11.4 |
| Insider 6 Months : 11.4 |
| Insider 3/6 Months : 23.2 |
|
| Guru Rank Number : 691 |
| Guru Rank Value : 2.3 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
7,330 |
7,330 |
7,330 |
7,330 |
| Total Buy Value |
$991,672 |
$991,672 |
$991,672 |
$991,672 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
6,815 |
22,740 |
| Total Sell Value |
$0 |
$0 |
$1,357,080 |
$4,648,975 |
| Total People Sold |
0 |
0 |
2 |
3 |
| Total Sell Transactions |
0 |
0 |
5 |
17 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Flatley Jay T |
Director |
• • – |
2021-05-04 |
4 |
AS |
$384.15 |
$1,536,600 |
D/D |
(4,000) |
152,933 |
|
20% |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2021-04-22 |
4 |
AS |
$402.02 |
$126,234 |
D/D |
(314) |
6,518 |
|
12% |
|
| Flatley Jay T |
Director |
• • – |
2021-04-20 |
4 |
AS |
$401.83 |
$1,607,320 |
D/D |
(4,000) |
156,933 |
|
17% |
|
| Torres Jose |
VP, Chief Accounting OfficerOf |
• – – |
2021-04-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6 |
|
17% |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2021-04-06 |
4 |
AS |
$423.44 |
$424,218 |
D/D |
(1,000) |
5,111 |
|
25% |
|
| Flatley Jay T |
Director |
• • – |
2021-04-06 |
4 |
AS |
$423.44 |
$1,693,740 |
D/D |
(4,000) |
160,933 |
|
25% |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2021-04-06 |
4 |
AS |
$423.44 |
$211,718 |
D/D |
(500) |
44,143 |
|
25% |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2021-04-05 |
4 |
AS |
$386.03 |
$386,030 |
D/D |
(1,000) |
6,111 |
|
33% |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2021-04-05 |
4 |
D |
$384.54 |
$50,375 |
D/D |
(131) |
5,461 |
|
- |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2021-04-05 |
4 |
AS |
$386.03 |
$115,809 |
D/D |
(300) |
44,643 |
|
33% |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2021-03-22 |
4 |
AS |
$416.24 |
$130,699 |
D/D |
(314) |
6,832 |
|
15% |
|
| Flatley Jay T |
Director |
• • – |
2021-03-16 |
4 |
AS |
$421.06 |
$1,684,240 |
D/D |
(4,000) |
164,933 |
|
17% |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2021-03-05 |
4 |
AS |
$402.24 |
$321,792 |
D/D |
(800) |
44,943 |
|
16% |
|
| Flatley Jay T |
Director |
• • – |
2021-03-02 |
4 |
AS |
$444.61 |
$1,778,440 |
D/D |
(4,000) |
168,933 |
|
10% |
|
| Mcginnis Karen K |
VP, Chief Accounting Officer |
• • – |
2021-02-18 |
4 |
AS |
$486.75 |
$324,176 |
D/D |
(666) |
1,538 |
|
-1% |
|
| Ragusa Robert P |
SVP, Global Quality & Ops |
• • – |
2021-02-17 |
4 |
D |
$494.24 |
$1,570,695 |
D/D |
(3,178) |
9,617 |
|
- |
|
| Ragusa Robert P |
SVP, Global Quality & Ops |
• • – |
2021-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,306 |
12,795 |
|
- |
|
| Ragusa Robert P |
SVP, Global Quality & Ops |
• • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
694 |
6,489 |
|
- |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2021-02-17 |
4 |
D |
$494.24 |
$1,072,501 |
D/D |
(2,170) |
7,185 |
|
- |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2021-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,379 |
9,355 |
|
- |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
482 |
4,976 |
|
- |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2021-02-17 |
4 |
D |
$494.24 |
$718,625 |
D/D |
(1,454) |
5,592 |
|
- |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2021-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
7,046 |
|
- |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
350 |
3,873 |
|
- |
|
| Desouza Francis A |
President and CEO |
• • – |
2021-02-17 |
4 |
D |
$494.24 |
$6,521,003 |
D/D |
(13,194) |
72,740 |
|
- |
|
3466 Records found
|
|
Page 10 of 139 |
|
|
3.39 (2.96%) 
